We'll know more about the company's medium-term prospects by the end of the year.

Researchers have used modified CRISPR to silence the extra chromosome 21 in Down syndrome cells, showing promising ...

The gene editing treatment targets the relatively common 1717-1G>A splicing mutation, which does not respond to many current CF therapies.

CRISPR Therapeutics (CRSP) stock dropped 11% after missing Q1 estimates badly. Regeneron's free gene therapy approval adds ...

Charles Gersbach and his colleagues are pursuing promising CRISPR technologies focused on controlling gene activity rather ...

Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.

The Pairwise Fulcrum® platform includes proprietary gene editing tools, enzymes, and trait libraries that enable precise genetic changes, unlocking plants’ inherent potential and significantly ...

There are plenty of reasons, though, to be bullish on the stock, not the least of which is its improved cash position. The ...

Cancer cells excel at evading detection, but subtle chemical differences set them apart from healthy cells. Now, a team of ...

Genome‑wide CRISPR screens in primary human T cells reveal human genes that promote or block HIV infection, uncovering potent ...

View CRISPR Therapeutics AG CRSP stock quote prices, financial information, real-time forecasts, and company news from CNN.

Qatar has taken a landmark step in precision medicine after Sidra Medicine became the first hospital in the country — and one ...